Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +47.30%
#3 Glidr Glidr +35.94%
#4 Cysic Cysic +32.50%
#5 Walrus Walrus +23.65%
#6 Tutorial Tutorial +23.18%
#7 Enso Enso +18.12%
#8 Humanity Humanity +18.02%
#9 Codatta Codatta +15.61%
#10 Huma Finance Huma Finance +13.74%
Coin of the day
EXOD EXOD
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Magenta Therapeutics, Inc. Magenta Therapeutics, Inc.

Magenta Therapeutics, Inc.

MGTA
Classement en actions #36943
Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development... Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development stage, dedicated to advancing therapies that leverage the transformative potential of stem cell transplantation for individuals afflicted with blood cancers, genetic illnesses, and autoimmune conditions. Among its key pipeline candidates is MGTA-117, an anti-CD117 antibody. This compound specifically targets hematopoietic stem cells (HSCs) and the genetically altered stem cells implicated in acute myeloid leukemia and myelodysplastic syndromes, and is currently progressing through Phase I/II clinical trials. Additionally, the company is developing a CD45-antibody drug conjugate, designed to target both HSCs and immune cells. This asset is in investigational new drug (IND) enabling studies, exploring its potential as a monotherapy for autoimmune diseases and in hematology-oncology transplant settings. Another therapeutic, MGTA-145, is undergoing Phase II clinical evaluation for its application in both autologous and allogeneic transplant procedures. Beyond these, Magenta boasts a cell therapy initiative featuring E478, a small molecule aryl hydrocarbon receptor antagonist, which is being explored for stem cell-based gene therapy and genome editing. The company actively engages in strategic alliances, including a research and clinical collaboration with AVROBIO, Inc. focused on treating lysosomal storage disorders. Furthermore, it partners with Beam Therapeutics, Inc. to investigate the utility of MGTA-117 as a conditioning regimen for patients with sickle cell disease and beta-thalassemia. Originally incorporated in 2015 as HSCTCo Therapeutics, Inc., the company adopted its current name, Magenta Therapeutics, Inc., in February 2016. Its corporate headquarters are situated in Cambridge, Massachusetts.
Prix de l'action
$0.6996
Dernière synchronisation: 2023-09-11
Capitalisation boursière
$2.19M
Changement (1 jour)
-7.74%
Changement (1 an)
0.00%
Pays
US
Échange Magenta Therapeutics, Inc. (MGTA)

Catégorie

Healthcare
Le prix MGTA avec la capitalisation boursière de B
Magenta Therapeutics, Inc. Magenta Therapeutics, Inc.
MGTA
$0.6996
Capitalisation boursière de Magenta Therapeutics, Inc.(MGTA)
Capitalisation boursière: $2.19M
En August 2026, Magenta Therapeutics, Inc. a une capitalisation boursière de $2.19M. Cela fait de Magenta Therapeutics, Inc. la 36943rd entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Magenta Therapeutics, Inc. du 2018 au 2026
MGTA par rapport au top 5 des plus populaires stocks
Prix pour MGTA L’actif B La capitalisation boursière de B Résultats
Magenta Therapeutics, Inc. Magenta Therapeutics, Inc.
$1,744,610 $2.19M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.452T +249,372,429.47%
Magenta Therapeutics, Inc. Magenta Therapeutics, Inc.
$1,436,817 $2.19M
Apple Inc. Apple Inc.
AAPL
$4.490T +205,376,798.65%
Magenta Therapeutics, Inc. Magenta Therapeutics, Inc.
$1,331,980 $2.19M
Alphabet Inc. Alphabet Inc.
GOOG
$4.162T +190,391,526.81%
Magenta Therapeutics, Inc. Magenta Therapeutics, Inc.
$1,176,438 $2.19M
Microsoft Corporation Microsoft Corporation
MSFT
$3.676T +168,158,567.47%
Magenta Therapeutics, Inc. Magenta Therapeutics, Inc.
$906,580 $2.19M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.833T +129,585,399.91%